6.7.12. Summary of evidence and guidelines for life-prolonging treatments of castrate-resistant disease. Summary of evidenceLETreatment for mCRPC will be influenced by which treatments patients have already been exposed to.4 RecommendationsStrength ratingEnsure that testosterone levels are confirmed to be < 50 ng/dL before diagnosing castrate-resistant PCa (CRPC).StrongCounsel, manage and treat patients with metastatic CRPC (mCRPC) in a multidisciplinary team.StrongTreat patients with mCRPC with life-prolonging agents.StrongOffer mCRPC patients somatic and/or germline molecular testing as well as testing for mismatch repair deficiencies or microsatellite instability.Strong 